EUCTR2010-024585-22-GB进行中（未招募）1 期
What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? - Ferinject® for iron deficiency in IPAH patients
Imperial College Academic Healthsciences Centre0 个研究点目标入组 39 人开始时间: 2011年2月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •We have carefully chosen the following entry criteria to clearly define our study group and reduce the potential for variation.
- •1. Males or females aged between 16–75 years old
- •2. PAH which is idiopathic, heritable or associated with anorexogens.
- •3. Iron deficiency as defined by any one of the following criteria:
- •sTfR levels > 28.1 nmol/l (where sTfR analysis is available) or one of the following: Ferritin < 37 ug/l; transferrin saturations < 16.4%; iron < 10.3 umol/l.
- •4*. Documented diagnosis of PAH by right heart catheterisation performed at any time prior to Screening showing: resting mean pulmonary artery pressure >25mmHg, pulmonary capillary wedge pressure =/< 15 mm Hg and normal or reduced cardiac output.
- •5. Six minute walking distance greater than 150m at entry;
- •6. Stable on an unchanged PAH therapeutic regime (any combination of endothelin receptor antagonist, phosphodiesterase inhibitor or prostacyclin analogue) for at least 1 month.
- •7. Able to provide written informed consent prior to any study-mandated procedures.
- •8. Female subjects of child-bearing potential are eligible to participate if they agree to use one of the following contraception methods:
- •- Abstinence
- •- Contraceptive methods with a failure rate of < 1%:
- •- Oral contraceptive, either combined or progestogen alone;
- •- Injectable progestogen;
- •- Implants of levonorgestrel;
- •- Estrogenic vaginal ring;
- •- Percutaneous contraceptive patches;
- •- Intrauterine device (IUD) or intrauterine system (IUS) that meets the <1% failure rate as stated in the product label;
- •- Male partner(s) sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study;
- •- Double barrier method: condom and occlusive cap (diaphragm or cervical/vault caps) plus vaginal spermicidal agent (foam/gel/film/cream/suppository).
- •*Patients who have not had a cardiac catheterisation prior to screening, but meet all other inclusion/exclusion criteria will be considered for the study if the clinical diagnosis is in keeping with idiopathic pulmonary arterial hypertension (IPAH). Inclusion of such patients should be discussed with the CI. These patients will be excluded at baseline if during the right heart catheterisation (RHC) the following criteria are not met: resting mean pulmonary artery pressure > 25mm Hg, pulmonary capillary wedge pressure =/< 15 mm Hg and normal or reduced cardiac output.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Unable to provide informed consent.
- •2. Clinically-significant renal disease (Creatinine clearance < 30 ml/min per 1.73 m2 calculated from CKD-Epi http://www.qxmed.com/renal/Calculate-CKD-EPI-GFR.php) or liver disease (including serum transaminases > 3 times upper limit of normal).
- •3. Haemoglobin concentration <10 g/dl.
- •4. Patients who meet any of the following criteria will be excluded:
- •Iron>27 umol/L, Ferritin>300 ug/L or Transferrin saturations >45%
- •5. Patients with moderate to severe hypophosphatemia as defined as <0.65mmol/L
- •6. Known to have haemoglobinopathy e.g. sickle cell disease, thalassaemia.
- •7. Admission to hospital related to PAH or change in PAH therapy within 1 month prior to Screening.
- •8. Evidence of left ventricular disease or significant lung disease on high-resolution CT scanning or lung function.
- •9. Acute or chronic infection or inflammation.
- •10. Significant uncontrolled asthma as judged by the investigator, eczema or atopic allergies.
- •11. Females who are lactating or pregnant.
- •12. Individuals known to have HIV, Hepatitis B or C or Creutzfeldt-Jakob disease.
- •13. Known hypersensitivity to Ferinject® or any of its excipients.
- •14. Evidence of disturbances in utilisation of iron.
- •15. Significant blood loss (e.g. GI bleed) within the last 3 months or history of menorrhagia.
- •16. Unable to perform a Cardiopulmonary Exercise Test i.e. due to syncope or musculoskeletal factors.
- •17. Patients who have received an investigational medicinal product within 30 days of entering the baseline visit
研究者
相似试验
进行中（未招募）
1 期
What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?Idiopathic or familial pulmonary arterial hypertensionMedDRA version: 19.0Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-024585-22-DEImperial College Academic Healthsciences Centre60
招募中
Unknown
Effect of intravenous iron supplementation on the level of hemoglobin in staged bilateral knee arthroplastyDiseases of the musculoskeletal system and connective tissueKCT0008823Chonnam National University Hospital Hwasun Hospital120
招募中
不适用
Effect of intravenous iron supplementation on the level of hemoglobin in revision hip and knee arthroplastyDiseases of the musculo-skeletal system and connective tissueKCT0005832Chonnam National University Hospital Hwasun Hospital120
进行中（未招募）
1 期
Effect of i.v. iron supplementation on white blood cells after kidney transplantatioAnemia and iron deficiency in renal transplant recipientsEUCTR2012-003915-73-ATMedizinische Universität Wien/Univ.klinik für Innere Medizin III/Abteilung für Nephrologie und Dialyse/Prof Josef Smolen
进行中（未招募）
1 期
Effects of intravenous administered iron in non-anemic iron deficient patients with colorectal cancer.Iron-deficiency in colorectal cancerMedDRA version: 20.0Level: PTClassification code 10009944Term: Colon cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10022970Term: Iron deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2019-003819-56-DKCentre for Surgical Science134